Biotech Co.* |
Pharma Co. |
Type/Product Area |
Terms/Details (Date) |
Acologix Inc.* |
Toray Industries Inc. (Japan) |
Toray gained exclusive rights in Japan to the hyperphosphatemia agent AC-200 |
Acologix maintains primary development responsibility for AC-200 (Phosphatonin); terms of the deal were not disclosed (6/19) |
Actelion Ltd. |
F. Hoffmann-La Roche Ltd. (Switzerland) |
Deal to develop and market Actelion's selective S1P1 receptor agonist, which is in Phase I trials for treating autoimmune disorders |
Actelion gets $75 up front and up to $555M in milestone payments for the first compound; it also would get royalties; they will share expenses after Phase II and would co-promote any resulting products, sharing profits equally (7/17) |
Acusphere |
GE Healthcare |
Acusphere got nonexclusive rights to use GE ultrasound contrast agent technology with its AI-700 product candidate |
Acusphere will use the technology with its AI-700 agent for assessing myocardial perfusion; GE gets $5M up front and $5M in one year; it would get $10M more after product approval (6/5) |
Alnylam |
Merck & Co. Inc. |
They amended existing deals, adding nine Merck targets and giving Merck a more active role in developing RNAi therapeutic products |
Alnylam would get $120M in milestones if three drugs are approved; Alnylam may select 3 of the 9 targets as joint development programs; Alnylam is entitled to accelerated R&D funding under the amended deal (7/6) |
Affibody AB* |
GE Healthcare |
Affibody will provide molecules for use against three disease targets selected by GE |
GE has an exclusive option to license imaging agents resulting from the deal; Affibody retains all rights outside in vivo diagnostics and medical imaging (6/19) |
Affymax Inc.* |
Takeda Pharmaceutical Co. Ltd. (Japan) |
Worldwide deal to develop and market Affymax's Phase II product Hematide for anemia; Takeda already had rights in Japan |
Affymax gets $105M up front and could get development and regulatory milestone payments of up to $280M, plus commercial milestones up to $150M, as well as royalties on sales outside the U.S.; Affymax has co-commercialization rights in the U.S. (6/27) |
Amaxa GmbH* |
Dharmacon Inc. (unit of Fisher Biosciences) |
Collaboration focused on delivery of siRNA agents into cells |
They will co-promote data generated using Dharmacon's siRNA libraries with Amaxa's Nucleofector delivery technology (6/6) |
Aradigm |
Novo Nordisk A/S (Denmark) |
Novo got additional rights to Aradigm technology for use in its inhaled insulin program |
Aradigm received $12M in exchange for the licenses, another $8M for a 1% reduction on sales royalties, and $7.5M from an eight- year note secured by product royalties (7/5) |
Archemix |
Elan Corp. plc (Ireland) |
Deal to develop aptamer drugs targeting IL-23 and other protein targets for treating autoimmune diseases |
Archemix gets $7M up front and is entitled to up to $350M in development and sales milestones, as well as royalties on any resulting sales; it also has certain co-promotion options (7/13) |
ARYx |
Procter & Gamble Pharmaceuticals Inc. |
P&G will develop and commercialize ARYx's Phase II product ATI-7505 for the treatment of gastrointestinal disorders |
ARYx gets $25M up front; total payments could reach $435M, including $250M prior to commercialization; it also would get royalties on sales; and ARYx has an option to co- develop and co-promote the drug (7/11) |
Avanir |
Healthcare Brands International |
HBI got rights in much of Europe to docosanol 10% cream for treating cold sores |
Avanir is entitled to up-front fees and milestone payments upon regulatory approvals in the licensed territory (7/6) |
Avid Radio- |
Schering AG (Germany) |
Collaboration to develop diagnostic imaging agents for Alzheimer's disease |
Schering has an option to gain exclusive rights to amyloid plaque-binding compounds from Avid for use with PET scan- ning technology; terms were not disclosed (7/14) |
BioCryst |
Green Cross Corp. (South Korea) |
Green Cross got rights in Korea to the investigational influenza neuraminidase inhibitor peramivir |
Green Cross will conduct trials in Korea; BioCryst gets a license fee and is entitled to milestone payments as well as double- digit royalties on sales; it also would share any profits from sales to the Korean government (6/14) |
BioSeek Inc.* |
GlaxoSmithKline plc (UK) |
Deal under which BioSeek will characterize compounds from GSK |
BioSeek will apply its BioMAP Systems to the compounds; terms of the deal were not disclosed (7/6) |
Caliper Life |
Wyeth Pharmaceuticals |
Deal for Caliper to conduct a high- throughput screening campaign for Wyeth |
Caliper unit NovaScreen Biosciences Corp. will screen 500,000 compounds against an inflammatory target; terms were not disclosed (6/26) |
Celera |
Specialty Laboratories |
Specialty got a nonexclusive license to Celera's risk markers for cirrhosis in those with hepatitis C virus |
Celera gets an up-front payment and would get royalties on commercial use of resulting tests (6/22) |
Celera |
Schering AG (Germany) |
Schering acquired Celera's small- olecule cathepsin S inhibitor program, which targets autoimmune diseases |
Celera gets $5M up front; development and commercial milestone payments could total $360M; Celera also would get royalties on any resulting sales (6/21) |
CoTherix Inc. |
Asahi Kasei Pharma Corp. (Japan) |
CoTherix got rights in North America and Europe to oral and inhaled formulations of Fasudil, a rho-kinase inhibitor |
The license covers development for pulmonary arterial hypertension, stable angina and other potential indications; Asahi Kasei gets $8.75M up front, along with potential milestone and royalty payments (6/28) |
CV |
Roche Palo Alto LLC |
CV acquired Asian rights to ranolazine, under an amendment to an existing agreement |
Roche is entitled to up-front, milestone and royalty payments; CV now has worldwide rights in all indications (6/22) |
Cytokinetics |
GlaxoSmithKline plc (UK) |
They extended for one year a deal begun in 2001; the focus is on centromere-associated protein E, a mitotic kinesin |
Two clinical-stage products already have come from the collaboration; terms of the extension were not disclosed(6/20) |
Cytori |
Cambrex Bio Science Walkersville Inc. (subsidiary of Cambrex Corp.) |
Cambrex got a co-exclusive license to adipose-derived stem cell products from Cytori |
Cambrex will market products globally for use in basic and translational research; Cytori would get royalty payments on all resulting product sales (6/13) |
Debiopharm |
Sigma-Tau Group (Italy) |
Debiopharm got rights to develop and market istaroxime, a Phase II product for treating acute heart failure syndromes |
Sigma-Tau, which retained marketing rights in certain European countries, gets an up-front fee along with potential milestone and royalty payments; Debiopharm will fund development; it would get royalties on Sigma-Tau sales (6/14) |
Depomed Inc. |
King Pharmaceuticals Inc. |
Deal for the commercialization of Depomed's metformin-based, approved diabetes product Glumetza |
King will assume responsibility for selling the product in the U.S. and get a portion of profits; Depomed retained a co- romotion option (6/28) |
Emergent |
Sanofi Pasteur (France) |
Sanofi got worldwide rights to proteins and related technology for development of a meningitis B vaccine |
They will jointly develop antigens as the basis of a multivalent subunit vaccine; Emergent gets €3M up front, development payments, and potential milestone and royalty payments (6/5) |
Emisphere |
F. Hoffmann-La Roche Ltd. (Switzerland) |
Deal to explore the use of Emisphere's eligen technology for new oral formulations of several Roche molecules |
The eligen technology is used to develop oral forms of injectable drugs; Roche will fund the research program (7/18) |
EvoGenix |
CSL Ltd. (Australia) |
Deal under which EvoGenix will apply its technologies to antibodies from CSL |
EvoGenix will get research payments and could get milestone and royalty payments on each resulting product (6/1) |
Evotec AG |
F. Hoffmann- La Roche Ltd. (Switzerland) |
Deal to discover and develop compounds against a target from Evotec for CNS diseases and other indications |
Roche has rights to develop resulting candidates, at which point Evotec would be entitled to €100M in milestone payments, plus royalties on any resulting sales (6/21) |
4SC AG |
Solvay Pharmaceuticals GmbH (Germany) |
Collaboration to identify molecules that bind to a target provided by Solvay |
The companies completed a similar project in 2005; terms and the target of the deal were not disclosed (6/28) |
Galapagos |
GlaxoSmithKline plc (UK) |
They entered a discovery and development deal covering multiple programs in the field of osteoarthritis |
Galapagos gets €4M up front, up to €130M in milestone payments for two marketable products and double-digit royalties on any resulting sales (6/7) |
GammaCan |
Life Therapeutics (Australia) |
Deal to develop VitiGam for treating metastatic melanoma |
The work is being done under a $1M grant being provided by the Israel-U.S. Binational Industrial Research and Development Foundation (6/21) |
GeneGo Inc.* |
Boehringer Ingelheim GmbH (Germany) |
BI licensed the MetaCore data-mining suite from GeneGo |
The technology primarily will be used for toxicogenomics research; terms of the deal were not disclosed (6/20) |
Genelabs |
Novartis AG (Switzerland) |
Deal to develop and market compounds from Genelabs' hepatitis C virus non-nucleoside program |
Genelabs gets $12.5M up front and $20M total over a two-year research term; it could get more than $175M more in milestone payments, and royalties on any resulting sales (6/5) |
Geron Corp. |
Corning Inc. |
Deal to develop and sell synthetic surface matrices for the growth of human embryonic stem cells |
Corning would sell resulting products, while Geron would receive royalties on those sales (6/22) |
Human |
Novartis AG (Switzerland) |
Deal to develop and market HGS' Albuferon for chronic hepatitis C and all other uses; Phase III trials of the drug are planned |
They will share costs and any profits in the U.S., while HGS would get royalties on sales outside the U.S.; HGS gets $45M up front and up to $507.5M in milestone and other payments (6/6) |
Illumina Inc. |
Johnson & Johnson Pharmaceutical Research & Development LLC |
Deal under which Illumina will provide genotyping services for J&J |
Illumina expects to genotype thousands of samples provided by J&J using its Infinium assay; terms of the deal were not disclosed (7/13) |
ImmunoGen |
Biotest AG (Germany) |
Biotest got exclusive rights to use Tumor-Activated Prodrug technology with antibodies targeting an undisclosed cancer target |
ImmunoGen gets $1M up front, up to $35.5M in milestone payments and royalties on any resulting sales; it also has certain rights to participate in U.S. development and commercialization (7/11) |
Innate Pharma |
Schering-Plough Corp. |
Innate licensed technology that strengthens its platform on manipulating Toll-like receptors |
Schering-Plough also got an option to certain rights outside Europe to TLR3 products, while Innate got certain options to TLR3 products from Schering-Plough in Europe (6/19) |
Intercell AG |
Novartis AG (Switzerland) |
Novartis got rights in much of the world to sell the Japanese encephalitis virus vaccine IC51, which is in Phase III trials |
Novartis will buy €30M of Intercell stock in an upcoming financing; Intercell also is entitled to up to €37M in milestone payments; Novartis also got first negotiation rights to certain other Intercell products (6/12) |
Isogenica |
AstraZeneca plc (UK) |
Deal to use Isogenica's CIS display technology to discover peptides against targets provided by AstraZeneca |
The deal follows a pilot study that began in 2004; terms were not disclosed (7/13) |
ISTA |
Senju Pharmaceuticals Co. Ltd. (Japan) |
ISTA gained U.S. rights to two drug candidates for glaucoma and other ophthalmic indications: iganidipine, and a new formulation of latanoprost |
Senju is entitled to up to $8M in up-front and milestone payments for each candidate, as well as royalties on resulting sales; the first product is a calcium channel blocker and the second, a prostaglandin (6/19) |
KineMed Inc.* |
NV Organon (the Netherlands) |
KineMed will attempt to find alternative applications for compounds formerly in Organon's clinical pipeline |
They jointly would determine a development and commercialization path for resulting compounds; terms were not disclosed (6/29) |
Locus |
Ono Pharmaceutical Co. Ltd. (Japan) |
Locus will use its technologies to design and develop preclinical drug candidates for Ono |
The target is a protein kinase selected by Ono; terms of the deal were not disclosed (7/6) |
Medivir AB |
Tibotec Pharmaceuticals Ltd. (unit of Johnson & Johnson) |
Tibotec got rights to two antiviral programs, and the companies extended an ongoing deal focused on the hepatitis C virus |
Tibotec got rights to a preclinical HIV pro- tease inhibitor project and to MIV-210, a polymerase inhibitor for HIV and hepatitis B; Medivir gets €2M up front in the potential €64M deal on the HIV program; the MIV-210 deal entails $0.5M up front and up to $30M in total; Medivir also would get royalties on resulting sales (6/30) |
Merrion |
F. Hoffmann- La Roche Ltd. (Switzerland) |
Deal to apply Merrion's oral drug delivery technology to an undisclosed Roche compound |
They will evaluate Merrion's GIPET technology in the feasibility study; terms of the deal were not disclosed (6/19) |
Metabolex |
Ortho-McNeil Inc. (unit of Johnson & Johnson) |
J&J got rights to Metabolex programs addressing metabolic diseases, including the compounds metaglidasen and MBX-2044; Metabolex got rights to a PPAR- delta agonist program |
Metabolex gets $40M in equity and convertible financings and up to $508M in development and sales milestones; it also would get royalties of up to 21% on resulting sales; Metabolex retained co-promotion rights in the U.S. (6/26) |
MGI Pharma |
Cilag GmbH (unit of Johnson & Johnson) |
J&J companies got exclusive rights outside North America to Dacogen, which is approved in the U.S. for treating myelodysplastic syndromes |
MGI and SuperGen Inc. will share a $10M up-front payment and up to $47M in milestone payments; MGI also will get $25M in research support and would get royalties on resulting sales (7/6) |
MorphoSys |
Novartis AG (Switzerland) |
They extended May 2004 therapeutic antibody collaboration through May 2011 |
MorphoSys will get increased research funding and license fees and remains entitled to milestone and royalty payments (6/23) |
Myogen Inc. |
Novartis AG (Switzerland) |
They extended for two years deal from 2003 to develop drugs for treating heart muscle disease |
Myogen will get research funding through October 2008, as well as potential milestone and royalty payments; it also has certain co-promotion and profit-sharing options (7/11) |
Nabi Bio- |
Kedrion SpA (Italy) |
Deal to develop and market Nabi's hepatitis C immune globulin product Civacir in Europe and the U.S. |
Kedrion will assume development costs for the product, which is nearing Phase II trials; Nabi, which would market the product in the U.S., is entitled to milestone and royalty payments (6/29) |
Origenis |
Alcon Research Ltd. |
They extended for two years deal to develop small-molecule drugs against ophthalmic targets chosen by Alcon |
Origenis is entitled to milestone and royalty payments; Alcon will get rights in ophthalmic and nasal applications; Origenis gets certain rights to all other uses of resulting drug candidates (7/5) |
QuatRx |
Solvay Pharmaceuticals (Belgium) |
QuatRx licensed a portfolio of 17-beta HSD Type 1 inhibitors |
The program was the subject of a partnership between Solvay and a QuatRx subsidiary; the program targets endometriosis and other indications (6/22) |
Radius* |
Eisai Co. Ltd. (Japan) |
Radius acquired rights to a class of selective estrogen receptor modulators |
The exclusive rights are worldwide, excluding Japan; terms of the deal were not disclosed (6/29) |
Resverlogix |
Medtronic Inc. |
Medtronic got exclusive rights to use ReVas compounds with drug-eluting devices for treating cardiovascular diseases |
After a feasibility stage, Resverlogix subsidiary RVX Therapeutics Inc. would be entitled to up-front, milestone and royalty payments; RVX could get up to $291M in the deal (7/19) |
Rib-X |
Wakunaga Pharmaceutical Co. Ltd. (Japan) |
Rib-X got rights to the broad- spectrum quinolone antibiotic WQ-3034, which has been in Phase II testing |
Wakunaga got an up-front fee and is entitled to milestone and royalty payments; Rib-X got worldwide rights (6/1) |
Ryogen LLC* |
R&D Systems Inc. (subsidiary of Techne Corp.) |
RDIS got nonexclusive rights to the patent directed to the Aminopeptidase P gene |
The XPNPEP2 gene is a marker for a number of diseases; terms of the deal were not disclosed (7/6) |
Serologicals |
Novozymes A/S (Denmark) |
Exclusive deal to explore the commercialization of recombinant human albumin for use in cell culture media formulations |
Serologicals subsidiary Celliance Corp. will work with Novozymes in the deal, which commits both to an exclusive supply agreement if certain feasibility mileposts are achieved (7/6) |
Sirion |
Senju Pharmaceutical Co. Ltd. (Japan) |
Sirion got U.S. rights to a a topical ophthalmic emulsion containing the steroid compound difluprednate |
U.S. Phase III trials of the product for inflammatory eye diseases are expected to begin in 2007; terms of the deal were not disclosed (6/22) |
Spherics Inc.* |
Takeda Pharmaceutical Co. Ltd. (Japan) |
Deal to apply Spherics' bioadhesive technologies to a Takeda compound |
The goal is to improve the performance of the oral compound; terms of the deal were not disclosed (6/28) |
SuperGen |
Mayne Pharma Ltd. (Australia) |
Mayne acquired North American rights to the oncology products Nipent and SurfaceSafe |
SuperGen gets $14M up front and up to $20M more if certain milestones are met (6/21) |
Tercica Inc. |
Ipsen SA (France) |
Ipsen got rights to market the IGF-1 deficiency product Increlex outside North America and Japan; Tercica got rights to sell Somatuline Autogel in North America; each also got rights to partner on the other's endocrine pipeline |
Tercica gets $12.5M up front and would get $18.8M upon Increlex approval in Europe; it would get royalties of 15% to 25%; also, Ipsen purchased $77.3M in Tercica stock, at $6.17 per share, representing 25% of Tercica; Ipsen received convertible notes and warrants that would allow it to increase its stake in Tercica to 40% (7/18) |
Theravance |
Astellas Pharma Inc. (Japan) |
Astellas gained rights to the investigational antibiotic telavancin in Japan, giving it worldwide rights to the drug |
Theravance gets $10M up front in the expanded deal and would get $5M upon approval in Japan; it received $90M earlier related to the license and is entitled to $131M more in milestone payments outside Japan, as well as royalties on sales (7/18) |
Vertex |
Janssen Pharmaceutica NV (unit of Johnson & Johnson) |
Janssen got exclusive rights to the hepatitis C virus product VX-950 in Europe, South America, the Middle East, Africa and Australia |
Vertex gets $165M up front and up to $380M based on successful development and launch in Janssen's territories; it also would get mid-20% royalties; Vertex retained North American rights (6/30) |
ViaCell Inc. |
Centocor Inc. (unit of Johnson & Johnson) |
Deal to evaluate ViaCell's cord blood- derived multipotent stem cells as a potential treatment for cardiac disease |
ViaCell gets an up-front payment; the companies will share research costs, while Centocor gets first rights to negotiate a development collaboration; they will use Cordis Corp.'s NOGA delivery system in the effort (6/13) |
Viropro Inc. |
BioChallenge (Tunisia) |
BioChallenge got rights to make and sell erythropoietin, interferon beta and growth factors in its territory |
The territory includes parts of Africa, Asia and Europe; Viropro anticipates $10.5M in revenues over four years, as well as royalties on sales of the therapeutic proteins (6/15) |
Notes: | # The information in the chart does not cover agricultural agreements or those between biotech companies. |
* Private companies are indicated with an asterisk. |
Unless otherwise noted, stock symbols listed are on the Nasdaq market. |
ASX = Australian Stock Exchange; FSE = Frankfurt Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; SWX = Swiss Stock Exchange; TSE = Toronto Stock Exchange; VSE = Vienna Stock Exchange. |
To read more on related topics, click on one of the words below.